AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 AUG 20 - (NewsRx.com & NewsRx.net) -- New vaccines against Alzheimer disease are targeting truncated beta-amyloid peptide species.
According to published research from France, "Vaccination against human beta-amyloid peptide (A-beta) has been shown to remove the amyloid burden produced in transgenic mice overexpressing the mutated human amyloid precursor protein (APP) gene. For human beings, the efficiency of this therapeutic strategy has to take into account the specificities of human amyloid, especially at the early stages of 'sporadic' Alzheimer's disease (AD)."
"A-beta 40/42 were previously quantified in tissues from our well-established brain bank, including non-demented individuals with both mild amyloid and tau pathologies, hence corresponding to the earliest stages of Alzheimer pathology," reported Nicolas Sergeant and collaborators at INSERM U422 and the Institut Pasteur de Lille. "Herein, we have adapted a proteomic method combined with western blotting and mass spectrometry for the characterization of insoluble A-beta extracted in pure-formic acid."
"We demonstrated that amino-truncated A-beta species represented more than 60% of all A-beta species, not only in full blown AD, but also, and more interestingly, at the earliest stage of Alzheimer pathology," stated Sergeant and his associates. "At this stage, A-beta oligomers were ...
Source: HighBeam Research, New vaccines against Alzheimer's targeting truncated beta-amyloid...